济川药业：子公司与泽德曼医药签署独占协议，获泽立美乳膏独家经营权

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Shanghai Zedeman Pharmaceutical Technology, allowing Jichuan to exclusively commercialize Zedeman's product, Zeli Mei (Bimekizumab) cream, in mainland China [1] Group 1: Agreement Details - The agreement involves a total payment of up to 190 million yuan (including tax) for upfront and milestone payments [1] - Zeli Mei is the first approved aromatase receptor modulator for the treatment of eczema in children aged 2 and above, as well as adults [1] Group 2: Market Potential - The drug has not yet been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory and is currently in the early stages of market expansion [1] - The market for atopic dermatitis drugs in China is projected to grow from 11 billion yuan in 2024 to 29.7 billion yuan by 2028 [1] Group 3: Strategic Implications - This transaction will enhance the company's product line and contribute to sustainable development, positively impacting future profitability and performance growth [1]